Novo Nordisk is chopping prices again for Wegovy, and its competitor is also planning its own price cut soon.

The drugmaker said Monday that it has started selling higher doses of the injectable obesity treatment for $349 a month to patients paying the full bill. That’s down from $499, and in line with terms of a drug pricing agreement outlined earlier this month by President Donald Trump’s administration.

Novo also started a temporary offer of $199 a month for the first two months of low doses of Wegovy and the drug’s counterpart for diabetes, Ozempic. The new pricing will be available at pharmacies nationwide, through home delivery and from some telemedicine providers.

Rival Eli Lilly also plans price breaks for its weight-loss drug Zepbound once it gets a new, multi-dose pen on the m

See Full Page